![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]()
Cambridge, Mass. (UPI) Jan 3, 2008 U.S. and British researchers are testing a new universal flu vaccine developed to tackle influenza pandemics. The British company Acambis said Phase I clinical and pre-clinical data suggest the firm's M2e-based universal influenza vaccine, Acam-Flu-A, has the potential to provide protection against strains of Influenza A. The vaccine targets the M2e peptide, which is found unchanged on the surface of all "A" strains of the influenza virus, including all pandemic influenza strains. The Phase 1 trial was a double-blind, placebo-controlled study conducted in three U.S. locations. The vaccine was shown to be immunogenic and well-tolerated, with no serious adverse events, the company said Thursday in a release. Acam-Flu-A is a recombinant vaccine that uses a hepatitis B core protein (HBc) to present M2e, the extracellular domain of the ion channel protein M2(5). The company said the vaccine has the potential to be both a "universal pandemic or pre-pandemic influenza vaccine and part of a universal seasonal vaccine." Related Links Hospital and Medical News at InternDaily.com
![]() ![]() The shutdown of an aging nuclear reactor in Canada has led to a global shortage of radioactive materials essential for medical tests and treatments for cancer and other diseases, industry officials said. |
![]() |
|
The content herein, unless otherwise known to be public domain, are Copyright Space.TV Corporation. AFP and UPI Wire Stories are copyright Agence France-Presse and United Press International. ESA Portal Reports are copyright European Space Agency. All NASA sourced material is public domain. Additional copyrights may apply in whole or part to other bona fide parties. Advertising does not imply endorsement, agreement or approval of any opinions, statements or information provided by Space.TV Corp on any Web page published or hosted by Space.TV Corp. Privacy Statement |